Sanofi
SNYHealthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Sanofi (SNY) P/E ratio
As of Nov 19, 2026, Sanofi (SNY) trades at a P/E ratio of 22.8×. Over the past ten years it has ranged from 3.5× (March 2021) to 32.2× (August 2015); the current reading is higher than 75% of that period. That is below the Drug Manufacturers General industry median of 25.3× and in line with the Healthcare sector median of 22.4×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 13.5× | (32.97%) |
| FY2024 | 20.1× | (5.22%) |
| FY2023 | 21.2× | 53.49% |
| FY2022 | 13.8× | 109.61% |
| FY2021 | 6.6× | 75.86% |
| FY2020 | 3.7× | (71.08%) |
| FY2019 | 12.9× | 7.79% |
| FY2018 | 12.0× | (50.31%) |
| FY2017 | 24.2× | 20.22% |
| FY2016 | 20.1× | (12.31%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 20.4× | (8.62%) |
| Jun 2026 | 22.3× | 65.96% |
| Mar 2026 | 13.5× | (0.02%) |
| Dec 2025 | 13.5× | 19.26% |
| 39 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GILD Gilead Sciences, Inc. compare | n/m |
| NVO Novo Nordisk A/S compare | 9.8× |
| BMY Bristol Myers Squibb Company compare | 12.9× |
| GSK GSK PLC Sponsored ADR compare | 16.4× |
| SNY Sanofi | 22.8× |
| AZN AstraZeneca PLC compare | 24.6× |
| AMGN Amgen Inc. compare | 25.2× |
| NVS Novartis AG compare | 28.8× |
| PFE Pfizer Inc. compare | 38.8× |
| Drug Manufacturers General industry median | 25.3× |
| Healthcare sector median | 22.4× |
| Market median | 16.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on SNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement